
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease. The company’s…
Full Article